NCL is upregulated in colorectal, gastric, breast, and lung cancers [32,44,45,46], and targeting NCL using aptamers was shown to reduce the invasiveness of breast cancer cells [45]. This evidence concerns the gene NUCLEOLIN and lung carcinoma.